Osimertinib nano-niosomes: surfactant effects, release kinetics, and cytotoxicity studies

Abstract

Aim:Osimertinib’s clinical application is limited by poor aqueous solubility and systemic toxicity. Nano-niosomal formulations can address these challenges by providing controlled release and enhancing delivery. To develop and systematically evaluate nano-niosomal formulations of osimertinib using different surfactants, focusing on physicochemical characteristics, release kinetics, and cytotoxic activity. Methods:Four niosomal formulations were prepared using Span 60, Tween 60, Pluronic F-127, and Brij 52 (each at a 1:1 cholesterol-to-surfactant ratio). Particle size, zeta potential, and entrapment efficiency were measured. In vitro drug release was analyzed using Franz diffusion cells and fitted to standard kinetic models. Cytotoxicity was assessed by MTT assay in KAIMRC-2, MDA-MB231, and HCT-116 cell lines. Vesicle morphology was visualized by transmission electron microscopy. Results:All nano-niosomal formulations showed nanoscale particle sizes (47–292 nm), negative zeta potentials (−18.7 to −26.5 mV), and high entrapment efficiencies (69.8%–76.2%). Release studies indicated Span 60, Tween 60, and Pluronic F-127 followed diffusion-controlled kinetics (Higuchi/Korsmeyer–Peppas model, R² up to 0.97), while Brij 52 provided a sustained zero-order release ( R² = 0.98). Compared to free osimertinib, all niosomal systems significantly prolonged release. Cytotoxicity studies demonstrated that all formulations enhanced anti-cancer effects, with Span 60-based niosomes exhibiting the greatest potency across cell lines. Conclusions:Optimized nano-niosomal encapsulation of osimertinib enables sustained and controlled drug release, improved cellular uptake, and enhanced cytotoxicity in vitro. Differences in surfactant composition critically influence formulation performance, supporting the further development of niosomal osimertinib as a promising strategy for oncological drug delivery applications.

Keywords

osimertinib / nano-niosomes / surfactants / drug release kinetics / cytotoxicity

References

[1] Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems——an overview. Adv Colloid Interface Sci. 2012; 183-184: 46-54.

[2] Ruckmani K, Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech. 2010; 11: 1119-27.

[3] Moammeri A, Chegeni MM, Sahrayi H, Ghafelehbashi R, Memarzadeh F, Mansouri A, et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater Today Bio. 2023; 23: 100837.

[4] Taymouri S, Varshosaz J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes. Adv Biomed Res. 2016; 5: 48.

[5] Deulkar DA, Kubde JA, Hatwar PR, Bakal RL, Motwani AN. Niosomes: A promising approach for targeted drug delivery. GSC Biol Pharm Sci. 2024; 29: 179-95.

[6] Riccardi D, Baldino L, Reverchon E. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field. J Transl Med. 2024; 22: 339.

[7] Witika BA, Bassey KE, Demana PH, Siwe-Noundou X, Poka MS. Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications. Int J Mol Sci. 2022; 23: 9668.

[8] Lamb YN. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC. Target Oncol. 2021; 16: 687-95.

[9] Lin Y, Hsiao C, Alshetaili A, Aljuffali IA, Chen E, Fang J. Lipid-based nanoformulation optimization for achieving cutaneous targeting: Niosomes as the potential candidates to fulfill this aim. Eur J Pharm Sci. 2023; 186: 106458.

[10] Gaikwad DS, Chougale RD, Patil KS, Disouza JI, Hajare AA. Design, development, and evaluation of docetaxel-loaded niosomes for the treatment of breast cancer. Futur J Pharm. 2023; 9: 43.

[11] Liga S, Paul C, Moacă E, Péter F. Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy. Pharmaceutics. 2024; 16: 223.

[12] Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S. Effect of Surfactant Type, Cholesterol Content and Various Downsizing Methods on the Particle Size of Niosomes. Iran J Pharm Res. 2018; 17: 1-11.

[13] Mowlaeifar MH, Niakousari M, Hosseini SMH, Eskandari MH. Effect of Cholesterol to Vitamin D3 and Span 60 to Tween 60 Ratios on the Characteristics of Niosomes: Variable Optimization Using Response Surface Methodology (RSM). J Food Qual. 2022; 2022: 7005531.

[14] Zolghadri S, Asad AG, Farzi F, Ghajarzadeh F, Habibi Z, Rahban M, et al. Span 60/Cholesterol Niosomal Formulation as a Suitable Vehicle for Gallic Acid Delivery with Potent In Vitro Antibacterial, Antimelanoma, and Anti-Tyrosinase Activity. Pharmaceuticals (Basel). 2023; 16: 1680.

[15] Khaliq NU, Lee J, Kim S, Sung D, Kim H. Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy. Pharmaceutics. 2023; 15: 2102.

[16] Gao S, Sui Z, Jiang Q, Jiang Y. Functional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications. Int J Nanomedicine. 2024; 19: 10283-305.

[17] Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010; 1: 374-80.